Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Merck KGaA, Darmstadt, Germany
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Stage IIIB or Stage IV NSCLC
Stable disease or a clinical response following first-line treatment, consisting of either chemotherapy alone or chemotherapy and radiotherapy. Subjects must have completed the first-line treatment at least 3 weeks prior to study entry
Eastern Cooperative Oncology Group (ECOG) performance status of greater than or equal to (\>=) 2
Ability to understand and willingness to sign a written informed consent
You may not be if
Received immunotherapy within 4 weeks prior to study entry
Received immunosuppressive drugs within 3 weeks prior to study entry
Subjects with known brain metastases
Past or current history of neoplasm other than lung carcinoma, except for curatively treated non-melanoma skin cancer, in situ carcinoma of the cervix or other cancer curatively treated and with no evidence of disease for at least 5 years
Autoimmune disease or immunodeficiency
Clinically significant hepatic, renal or cardiac dysfunction
Subjects with clinically significant active infection
Pregnant or breast feeding women, women of childbearing potential, unless using effective contraception as determined by the investigator
